Affiliation:
1. Khanty-Mansiysk State Medical Academy
2. Peoples’ Friendship University of Russia named after Patrice Lumumba
Abstract
Introduction. Uterine fibroids are the most common disease of the female reproductive system. If indicated, the main organpreserving method of treatment is myomectomy. However, according to many researchers, women who have undergone conservative myomectomy are at a higher risk of developing complications during pregnancy such as placenta previa, placental disorders, and uterine scar failure.Aim. To identify the features of the course of pregnancy, childbirth and perinatal outcome in women with a uterine scar after conservative myomectomy who received pregravid preparation.Materials and methods. A retrospective study included an analysis of 159 outpatient histories of women planning pregnancy after conservative myomectomy, including the birth histories of 109 pregnant women aged 29–40 years who delivered at the Perinatal Center of the Regional Clinical Hospital in Khanty-Mansiysk from 2011 to 2021 in order to study the characteristics of the course of pregnancy in women with a scar on the uterus after conservative myomectomy.Results. When analyzing the data, the following statistically significant differences between the groups were revealed: the first trimester of pregnancy in women with a uterine scar compared with the control group was more often complicated by chorion presentation, threatened miscarriage, urinary tract infection and early toxicosis (p < 0.05); in the second trimester of pregnancy in group 1, there were more often threatening preterm labor and placental disorders (p < 0.05), the majority of women with a scar on the uterus after myomectomy (77.8%) were delivered by caesarean section, in contrast to the control group (9.7%) (p < 0.05).Conclusion. The data we obtained on the course of pregnancy, childbirth and perinatal outcomes after myomectomy reflected the need and effectiveness of preconception preparation in this contingent of women.
Reference19 articles.
1. Kiesler ZG, Hunter MI, Balboula AZ, Patterson AL. Periostin’s role in uterine leiomyoma development: a mini-review on the potential periostin poses as a pharmacological intervention for uterine leiomyoma. Arch Gynecol Obstet. 2024. https://doi.org/10.1007/s00404-024-07435-z.
2. Koga K, Fukui M, Fujisawa M, Suzukamo Y. Impact of diagnosis and treatment of uterine fibroids on quality of life and labor productivity: The Japanese online survey for uterine fibroids and quality of life (JOYFUL survey). J Obstet Gynaecol Res. 2023;49(10):2528–2537. https://doi.org/10.1111/jog.15758.
3. El Sabeh M, Borahay MA. The Future of Uterine Fibroid Management: a More Preventive and Personalized Paradigm. Reprod Sci. 2021;28(11):3285–3288. https://doi.org/10.1007/s43032-021-00618-y.
4. Nieh C, Mabila SL. Incidence and health care burden of uterine fibroids among female service members in the active component of the U.S. Armed Forces, 2011–2022. MSMR. 2024;31(2):9–15. Available at: https://europepmc.org/article/MED/38466970.
5. Kamkhen VB, Zhaymyrzaeva GА. Uterine fibroids in women of fertile age: dimensions of nodes and clinical manifestations. Vestnik KazNMU. 2020;(3):12–14. (In Russ.) Available at: https://cyberleninka.ru/article/n/mioma-matki-u-zhenschin-fertilnogo-vozrasta-razmery-uzlov-iklinicheskie-proyavleniya.